• Alkermes plc, of Dublin, reported revenue from its second quarter ending Sept. 30 totaling $139.8 million, besting analyst estimates of $137.5 million. Revenue from its five key commercial products grew 38 percent year over year to $101 .5 million. Among product revenues included $62.6 million from manufacturing and royalty revenue for long-acting atypical antipsychotic franchise (Risperdal Consta, Invega Sustenna/Xeplion), while manufacturing and royalty revenue from Type II diabetes drug Bydureon (long-acting exenatide) totaled $7 million. Net sales of alcohol dependence drug Vivitrol (naltrexone extended release) totaled $19.2 million for the quarter, a 26 percent increase over the same quarter in 2012. The company reported net income totaling $31.8 million, or 22 cents per share, missing estimates by 1 cent. As of Sept. 30, Alkermes had a cash balance of about $395.2 million. The firm’s shares (NASDAQ:ALKS) closed Thursday at $35.20, down 43 cents.

• Cell Therapeutics Inc., of Seattle, reported total third-quarter revenues of $400,000, solely attributable to net product sales of cancer drug Pixuvri (pixantrone), which is approved in the European Union. The company’s net loss for the three-month period was $22.4 million, or 20 cents per share. Analysts had predicted a loss of 17 cents per share. As of Sept. 30, the firm had about $27.2 million in cash. Shares of Cell Therapeutics (NASDAQ:CTIC) closed Thursday at $1.76, down 3 cents.

• Exelixis Inc., of South San Francisco, reported net product revenue for Cometriq (cabozantinib) of $4.8 million in the third quarter. The multikinase inhibitor drug is approved for medullary thyroid cancer, and Exelixis is conducting a pivotal Phase III study to expand use into the larger metastatic castration-resistant prostate cancer space. The firm reported net revenues of $5.5 million for the quarter. Its net loss totaled $67. 1 million, or 36 cents per share, beating analyst estimates by a penny. Cash, equivalents and long-term investments totaled $464.7 million as of Sept. 30. Shares of Exelixis (NASDAQ:EXEL) closed Thursday at $4.93, down 15 cents.

• Intermune Inc., of Brisbane, Calif., reported third quarter revenue of $19.7 million for idiopathic pulmonary fibrosis drug Esbriet (pirfenidone), ahead of consensus estimates of $16.6 million, which the firm attributed in part to new country launches. Esbriet was launched in the UK and Italy in the third quarter, as well as in Finland and Ireland. Intermune posted a net loss of $49.9 million, or 61 cents per share, a narrower-than-expected loss compared to analyst estimates of 71 cents per share. As of Sept. 30, the firm had cash, equivalents and available-for-sale securities totaling about $337.2 million. Shares of Intermune (NASDAQ:ITMN) closed Thursday at $14.07, up 81 cents.

• Viropharma Inc., of Exton, Pa., posted net sales of $113 million for the third quarter, with the increase over last year’s $91 million in sales attributed primarily to growth in U.S. sales of hereditary angioedema drug Cinryze (C1 esterase). U.S. sales contributed to $102 million of the total. Net income totaled $4 million, or 6 cents per share, topping consensus estimates by 1 cent. As of Sept. 30, the company had a cash position of about $275 million. Shares of Viropharma (NASDAQ:VPHM) gained $1.65 Thursday to close at $38.81.